Thursday, November 02, 2017 9:05:07 AM
Agreed, given what I think is great results from Phase II studies in both Pegunigalsidase and DNAse, and the new Cheisi deal, I think now is a good time to buy.
Also in case anyone is interested, I did quite a bit of desk research into the science behind OPRX-106 for Ulcerative Colitis and except for one area that I can't be very clear on the science checks out and fits quite beautifully with OPRX-106 design.
In a brief explanation:
The platform makes the anti-TNF product inside carrot plant cells. These carrot plant cells are vascular plant cells that can't be broken down by our digestive system. Therefore the cells pass though the stomach acids, bile, and small intestine unaffected. These zones have different acidic or alkaline levels. However, once they reach the large intestine/colon, the acidity reaches around neutral pH levels and that is why the bacterial flora grow and live there. The bacteria in the large intestine/colon can breakdown the cellulose cell wall of vascular plant cells, thereby releasing the anti-TNF drug into the large intestine, hence being released in the exact location of the body affected in Ulcerative Colitis.
This I understand is one reason why PLX chose to go for the Ulcerative colitis indication, as it have the production platform itself allows specific benefits.
The only other way to treat Ulcerative Colitis with anti-TNF is by IV infusion which is both, less targeted and more inconvenient.
I'm not sure if the cost would be much lower than other anti-TNF treatment given the totality of the dosage as the oral formulation is given daily, over time isn't too much lower than the intermittent IV dosage. But perhaps also an added advantage PLX has here is the efficiency of anti-TNF production that can also allow us to undercut the competition. However of course PLX will want to keep the cost just under current prices I assume and let convenience, improved targeting and hopefully positive clinical data do the selling.
Recent PLX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 09:00:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 09:00:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 11:02:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 10:56:02 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/17/2024 09:05:17 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/17/2024 09:00:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 11:20:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 10:59:36 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/02/2024 11:36:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 11:56:21 AM
- Levicept Appoints Eliot Forster as CEO • GlobeNewswire Inc. • 11/30/2023 09:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2023 12:50:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 12:22:32 PM
- Upcoming Earnings Release Paired With Price Target Raise Sends Stock Soaring • AllPennyStocks.com • 10/31/2023 08:40:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/20/2023 10:50:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/03/2023 09:00:50 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM